NOT FOR DISTRIBUTION
Header cover image

Market Cap

€16.0b

Last Updated

2021/04/10 18:35 UTC

Data Sources

Company Financials +

Executive Summary

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. More Details


Snowflake Analysis

Outstanding track record with adequate balance sheet.


Similar Companies

Share Price & News

How has Hologic's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HO1 is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: HO1's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-2.2%

HO1

3.4%

DE Medical Equipment

0.8%

DE Market


1 Year Return

68.2%

HO1

44.1%

DE Medical Equipment

44.3%

DE Market

Return vs Industry: HO1 exceeded the German Medical Equipment industry which returned 42.3% over the past year.

Return vs Market: HO1 exceeded the German Market which returned 44% over the past year.


Shareholder returns

HO1IndustryMarket
7 Day-2.2%3.4%0.8%
30 Day7.7%5.7%4.6%
90 Day-5.5%10.9%9.0%
1 Year68.2%68.2%45.9%44.1%49.0%44.3%
3 Year107.2%107.2%95.7%87.4%24.6%13.8%
5 Year94.8%94.8%329.1%313.3%54.9%32.9%

Long-Term Price Volatility Vs. Market

How volatile is Hologic's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Hologic undervalued compared to its fair value and its price relative to the market?

13.86x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: HO1 (€61.02) is trading above our estimate of fair value (€33)

Significantly Below Fair Value: HO1 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: HO1 is good value based on its PE Ratio (13.8x) compared to the DE Medical Equipment industry average (46.5x).

PE vs Market: HO1 is good value based on its PE Ratio (13.8x) compared to the German market (27.8x).


Price to Earnings Growth Ratio

PEG Ratio: HO1's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: HO1 is good value based on its PB Ratio (5.8x) compared to the DE Medical Equipment industry average (8x).


Future Growth

How is Hologic forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?

-37.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HO1's earnings are forecast to decline over the next 3 years (-37.7% per year).

Earnings vs Market: HO1's earnings are forecast to decline over the next 3 years (-37.7% per year).

High Growth Earnings: HO1's earnings are forecast to decline over the next 3 years.

Revenue vs Market: HO1's revenue is expected to decline over the next 3 years (-9.8% per year).

High Growth Revenue: HO1's revenue is forecast to decline over the next 3 years (-9.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HO1's Return on Equity is forecast to be high in 3 years time (23.8%)


Past Performance

How has Hologic performed over the past 5 years?

9.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HO1 has high quality earnings.

Growing Profit Margin: HO1's current net profit margins (30.5%) are higher than last year (2.4%).


Past Earnings Growth Analysis

Earnings Trend: HO1's earnings have grown by 9.4% per year over the past 5 years.

Accelerating Growth: HO1's earnings growth over the past year (1613.5%) exceeds its 5-year average (9.4% per year).

Earnings vs Industry: HO1 earnings growth over the past year (1613.5%) exceeded the Medical Equipment industry 44.3%.


Return on Equity

High ROE: HO1's Return on Equity (42.2%) is considered outstanding.


Financial Health

How is Hologic's financial position?


Financial Position Analysis

Short Term Liabilities: HO1's short term assets ($2.6B) exceed its short term liabilities ($1.1B).

Long Term Liabilities: HO1's short term assets ($2.6B) do not cover its long term liabilities ($3.2B).


Debt to Equity History and Analysis

Debt Level: HO1's debt to equity ratio (85.5%) is considered high.

Reducing Debt: HO1's debt to equity ratio has reduced from 166.1% to 85.5% over the past 5 years.

Debt Coverage: HO1's debt is well covered by operating cash flow (51.3%).

Interest Coverage: HO1's interest payments on its debt are well covered by EBIT (17.3x coverage).


Balance Sheet


Dividend

What is Hologic current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HO1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HO1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HO1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HO1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HO1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure


CEO

Steve MacMillan (56 yo)

7.33yrs

Tenure

US$14,125,674

Compensation

Mr. Stephen P. MacMillan, also known as Steve, has been the Chairman of the Board at Hologic Inc. since June 17, 2015 and its Chief Executive Officer and President since December 9, 2013. Mr. MacMillan ser...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD14.13M) is above average for companies of similar size in the German market ($USD5.27M).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: HO1's management team is considered experienced (3.7 years average tenure).


Board Members

Experienced Board: HO1's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: HO1 insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Hologic, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hologic, Inc.
  • Ticker: HO1
  • Exchange: DB
  • Founded: 1985
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$18.972b
  • Listing Market Cap: US$15.965b
  • Shares outstanding: 257.66m
  • Website: https://www.hologic.com

Number of Employees


Location

  • Hologic, Inc.
  • 250 Campus Drive
  • Marlborough
  • Massachusetts
  • 1752
  • United States

Listings


Biography

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/10 18:35
End of Day Share Price2021/04/09 00:00
Earnings2020/12/26
Annual Earnings2020/09/26


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.